TD Cowen Forecasts Strong Price Appreciation for Revolution Medicines (NASDAQ:RVMD) Stock

Revolution Medicines (NASDAQ:RVMD) had its price objective raised by analysts at TD Cowen from $250.00 to $270.00 in a research note issued to investors on Thursday, Benzinga reports. The brokerage currently has a “buy” rating on the stock. TD Cowen‘s price objective suggests a potential upside of 40.42% from the company’s previous close.

Several other research firms have also commented on RVMD. William Blair began coverage on shares of Revolution Medicines in a report on Friday, October 16th. They issued an “outperform” rating on the stock. Sanford C. Bernstein lifted their price objective on Revolution Medicines from $151.00 to $179.00 and gave the company a “market perform” rating in a research note on Friday, August 21st. Piper Sandler lifted their price objective on Revolution Medicines from $210.00 to $222.00 and gave the company an “overweight” rating in a research note on Thursday. Evercore reissued an “outperform” rating and issued a $320.00 price objective on shares of Revolution Medicines in a report on Thursday, August 27th. Finally, Truist Financial restated a “buy” rating and issued a $261.00 target price (up from $241.00) on shares of Revolution Medicines in a research note on Thursday. One investment analyst has rated the stock with a Strong Buy rating, twenty-one have issued a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Revolution Medicines presently has an average rating of “Moderate Buy” and an average price target of $263.15.

Revolution Medicines Stock Performance

Shares of RVMD stock traded up $14.63 during trading hours on Thursday, hitting $192.28. The company’s stock had a trading volume of 4,496,326 shares, compared to its average volume of 1,940,895. The company has a 50 day moving average of $196.88 and a 200 day moving average of $157.56. The stock has a market cap of $41.21 billion, a PE ratio of -21.11 and a beta of 1.44. The company has a current ratio of 11.38, a quick ratio of 11.38 and a debt-to-equity ratio of 0.40. Revolution Medicines has a 12-month low of $58.91 and a 12-month high of $224.31.

Revolution Medicines (NASDAQ:RVMD) last released its quarterly earnings data on Wednesday, November 4th. The company reported ($1.90) earnings per share for the quarter, topping analysts’ consensus estimates of ($2.35) by $0.45. The business had revenue of $197.56 million during the quarter, compared to analyst estimates of $25.58 million. During the same quarter in the previous year, the company earned ($1.61) EPS. On average, sell-side analysts forecast that Revolution Medicines will post -8.94 EPS for the current fiscal year.

Insider Buying and Selling

In other Revolution Medicines news, insider Stephen Kelsey sold 92,531 shares of the company’s stock in a transaction dated Friday, September 11th. The shares were sold at an average price of $202.36, for a total value of $18,724,573.16. Following the completion of the transaction, the insider owned 291,876 shares in the company, valued at approximately $59,064,027.36. This represents a 24.07% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Mark Goldsmith sold 80,000 shares of the company’s stock in a transaction dated Friday, August 21st. The stock was sold at an average price of $209.20, for a total transaction of $16,736,000.00. Following the completion of the transaction, the insider owned 267,330 shares of the company’s stock, valued at approximately $55,925,436. This trade represents a 23.03% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 290,991 shares of company stock valued at $59,422,765 in the last ninety days. Company insiders own 7.60% of the company’s stock.

Hedge Funds Weigh In On Revolution Medicines

Several institutional investors and hedge funds have recently modified their holdings of the business. Burkett Financial Services LLC acquired a new position in Revolution Medicines in the 3rd quarter worth about $27,000. Contravisory Investment Management Inc. purchased a new position in Revolution Medicines during the second quarter worth approximately $32,000. Johnson Financial Group Inc. purchased a new position in Revolution Medicines during the second quarter worth approximately $37,000. Silvant Capital Management LLC acquired a new stake in Revolution Medicines in the second quarter valued at approximately $41,000. Finally, Northwestern Mutual Wealth Management Co. acquired a new stake in Revolution Medicines in the second quarter valued at approximately $41,000. Hedge funds and other institutional investors own 94.34% of the company’s stock.

Revolution Medicines News Summary

Here are the key news stories impacting Revolution Medicines this week:

• Positive Sentiment: Strong early Rasonque sales: Revolution Medicines reported $197.6 million in third-quarter revenue, beating estimates, with Rasonque generating that amount in just five weeks after its U.S. launch. The company said more than 5,000 patients had been treated. The quarterly loss per share also came in narrower than analysts expected. Zacks article on Q3 results and Rasonque uptake
• Positive Sentiment: Analyst targets moved higher: HC Wainwright raised its target to $350 and maintained a Buy rating. RBC lifted its target to $321 with an Outperform rating; Guggenheim, Truist and TD Cowen also raised targets and retained positive ratings. These revisions signal optimism about the drug’s commercial potential and pipeline. HC Wainwright recommendations RBC target increase
• Neutral Sentiment: Long-term opportunity, but expectations are high: Rasonque’s clinical results and potential expansion into other solid tumors support the pipeline outlook. However, commentary noted that RVMD’s roughly $40 billion valuation already reflects substantial expectations, making sustained launch growth and upcoming clinical results important. Seeking Alpha analysis of Q3 results
• Negative Sentiment: Some long-range forecasts were cut: Brookline Capital Markets lowered its FY2029 EPS estimate to $8.49 from $8.94 and its FY2030 estimate to $17.41 from $18.15, though it kept a Buy rating and a $318 target.

Revolution Medicines Company Profile

Revolution Medicines, Inc is a biotechnology company focused on developing targeted therapies for patients with RAS-driven cancers. Founded in 2014 and headquartered in Redwood City, California, the company’s research centers on RAS proteins, which can contribute to the growth of many cancers.

The company’s pipeline includes drug candidates designed to inhibit mutant RAS proteins, including daraxonrasib (RMC-6236), which targets multiple RAS variants, and candidates directed at specific KRAS mutations.